Scinai Immunotherapeutics Ltd.
SCNI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | -88.1% | – | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,062.2% | – | – | – |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 728.9% | – | – | – |
| EPS Diluted | 6 | -16.8 | -30.8 | -80 |
| % Growth | 135.7% | 45.5% | 61.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |